Document Detail


Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion.
MedLine Citation:
PMID:  20609474     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Azacitidine is currently the only drug to have shown a significant survival benefit over conventional care regimens in patients with International Prognostic Scoring System (IPSS) intermediate-2 (Int-2) and high-risk myelodysplastic syndromes (MDS), establishing it as an important new treatment for these individuals. However, several aspects of the practical use of azacitidine remain uncertain. This manuscript outlines recommendations discussed by a panel of experts, providing a practical guide for physicians to ensure optimal management of Int-2 and high-risk patients receiving azacitidine.
Authors:
Pierre Fenaux; David Bowen; Norbert Gattermann; Eva Hellström-Lindberg; Wolf-Karsten Hofmann; Michael Pfeilstöcker; Guillermo Sanz; Valeria Santini
Related Documents :
21226684 - The effect of geriatric and palliative medicine education on the knowledge and attitude...
21395194 - A systematic review of interventions to improve handwriting.
7974474 - Influencing physician practice patterns.
23280714 - Emerging importance of geographical indications and designations of origin - authentica...
16911604 - Neuromodulatory therapies in female pelvic medicine and reconstructive surgery: biologi...
20505394 - Academic retainer medicine: an innovative business model for cross-subsidizing primary ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2010-07-06
Journal Detail:
Title:  Leukemia research     Volume:  34     ISSN:  1873-5835     ISO Abbreviation:  Leuk. Res.     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-09-27     Completed Date:  2010-11-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7706787     Medline TA:  Leuk Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  1410-6     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 Elsevier Ltd. All rights reserved.
Affiliation:
Hôpital Avicenne, Assistance Publique, Hôpitaux de Paris and Paris 13 University, Bobigny, France. pierre.fenaux@avc.aphp.fr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antimetabolites, Antineoplastic
Azacitidine / therapeutic use*
Expert Testimony*
Humans
Myelodysplastic Syndromes / drug therapy*
Risk
Chemical
Reg. No./Substance:
0/Antimetabolites, Antineoplastic; 320-67-2/Azacitidine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Placental amino acid transport and placental leptin resistance in pregnancies complicated by materna...
Next Document:  Polybrominated diphenyl ethers (PBDEs) in the indoor environment and associations with prenatal expo...